| Range: | 0.185-1.79 | Vol Avg: | 3295660 | Last Div: | 0 | Changes: | 0 |
| Beta: | 0.08 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Nov 05 2021 | Empoloyees: | 65 | ||
| CUSIP: | N5436L101 | CIK: | 0001874252 | ISIN: | NL0015000LC2 | Country: | DE |
| CEO: | Mr. Guido Baechler | Website: | https://mainzbiomed.com | ||||
MYNZ 0.23 Stock Price Mainz Biomed B.V.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow